{
    "root": "8cb6cfed-487e-4351-8f48-0be3cc5c2d6d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FYLNETRA",
    "value": "20250425",
    "ingredients": [
        {
            "name": "PEGFILGRASTIM",
            "code": "3A58010674",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00019"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "fylnetra leukocyte growth factor indicated decrease incidence infection , manifested febrile neutropenia , patients non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated clinically significant incidence febrile neutropenia . ( 1.1 ) increase survival patients acutely exposed myelosuppressive doses radiation ( hematopoietic subsyndrome acute radiation syndrome ) . ( 1.2 ) limitations fylnetra indicated mobilization peripheral blood progenitor cells hematopoietic stem cell transplantation .",
        "doid_entities": [
            {
                "text": "neutropenia (DOID:1227)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1227"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "subsyndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_57145"
            },
            {
                "disease": "acute radiation syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_454831"
            }
        ]
    },
    "contraindications": {
        "text": "patients cancer receiving myelosuppressive chemotherapy 6 mg administered subcutaneously per chemotherapy cycle . ( 2.1 ) administer 14 days 24 hours cytotoxic chemotherapy . ( 2.1 ) weight based dosing pediatric patients weighing less 45 kg ; refer table 1 . ( 2.3 ) patients acutely exposed myelosuppressive doses radiation two doses , 6 mg , administered subcutaneously one week apart . administer first dose soon possible suspected confirmed exposure myelosuppressive doses radiation , second dose one week . ( 2.2 ) weight based dosing pediatric patients weighing less 45 kg ; refer table 1 . ( 2.3 )",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fylnetra single-dose prefilled syringe manual fylnetra ( pegfilgrastim-pbbk ) injection clear , colorless slightly yellow , preservative-free solution supplied prefilled single-dose syringe manual containing 6 mg pegfilgrastim-pbbk , supplied 27-gauge , 1/2-inch needle ultrasafe plustm passive needle guard . needle cap prefilled syringe made natural rubber latex . fylnetra provided dispensing pack containing one sterile 6 mg/0.6 ml prefilled syringe ( ndc 70121-1627-1 ) . fylnetra prefilled syringe bear graduation marks intended deliver entire contents syringe ( 6 mg/0.6 ml ) direct . prefilled syringe recommended direct pediatric patients weighing less 45 kg require doses less full contents syringe . store refrigerated 36\u00b0f 46\u00b0f ( 2\u00b0c 8\u00b0c ) carton protect light . shake . discard syringes stored room temperature [ 68\u00b0f 77\u00b0f ( 20\u00b0c 25\u00b0c ) ] 72 hours . avoid freezing ; frozen , thaw refrigerator . discard syringe frozen .",
    "adverseReactions": "fylnetra contraindicated patients history serious allergic pegfilgrastim products filgrastim products . included anaphylaxis [ ( 5.3 ) ] .",
    "indications_original": "FYLNETRA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1.1) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2) Limitations of Use FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.",
    "contraindications_original": "Patients with cancer receiving myelosuppressive chemotherapy 6 mg administered subcutaneously once per chemotherapy cycle. (2.1) Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy. (2.1) Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. (2.3) Patients acutely exposed to myelosuppressive doses of radiation Two doses, 6 mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and a second dose one week after. (2.2) Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. (2.3)",
    "warningsAndPrecautions_original": "FYLNETRA single-dose prefilled syringe for manual use \n                  \n                  FYLNETRA (pegfilgrastim-pbbk) injection is a clear, colorless to slightly yellow, preservative-free solution supplied in a prefilled single-dose syringe for manual use containing 6 mg pegfilgrastim-pbbk, supplied with a 27-gauge, 1/2-inch needle with an UltraSafe PlusTM Passive Needle Guard.\n                  The needle cap on the prefilled syringe is not made with natural rubber latex.\n                  FYLNETRA is provided in a dispensing pack containing one sterile 6 mg/0.6 mL prefilled syringe (NDC 70121-1627-1).\n                  FYLNETRA prefilled syringe does not bear graduation marks and is intended only to deliver the entire contents of the syringe (6 mg/0.6 mL) for direct administration. Use of the prefilled syringe is not recommended for direct administration for pediatric patients weighing less than 45 kg who require doses that are less than the full contents of the syringe.\n                  Store refrigerated between 36\u00b0F to 46\u00b0F (2\u00b0C to 8\u00b0C) in the carton to protect from light. Do not shake. Discard syringes stored at room temperature\u00a0[68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C)] for more than 72 hours. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard syringe if frozen more than once.",
    "adverseReactions_original": "FYLNETRA is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis [see Warnings and Precautions (5.3)].",
    "drug": [
        {
            "name": "FYLNETRA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00019"
        }
    ]
}